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SUMMARY
Clinical and environmental isolates of pathogens are often unique and may be unculturable, yielding a very limited amount
of DNA for genetic studies. Cryptosporidium in particular are diﬃcult to propagate. Whole genome ampliﬁcation (WGA)
is a valuable technique for amplifying genomic material. In this study, we tested 5 WGA commercial kits using
Cryptosporidium clinical isolates. DNA of 5 C. hominis and 5 C. parvum clinical isolates and C. parvum IOWA reference
strain were used. The majority of the samples were ampliﬁed by all of the kits tested. The integrity and ﬁdelity of the
ampliﬁed genomic DNAwere assessed by sequence analysis of several PCR products of varying length.We found evidence
that one kit in particular may be more error prone while another seemed the more suitable kit for Cryptosporidium clinical
samples, generating high molecular weight DNA from all the samples with high ﬁdelity. Thus WGA was found to be
a useful technique for producing ampliﬁed DNA suitable for downstream genotyping techniques and archiving of
Cryptosporidium clinical isolates.
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INTRODUCTION
The availability of adequate amounts of high quality
genomic DNA is essential for genetic studies such as
diagnosis and genotyping. Genotyping and subtyp-
ing of clinical and environmental isolates is desirable
as it allows source tracking and better understanding
of molecular epidemiology and population structure
(Anderson et al. 2000; Han et al. 2000; Mallon
et al. 2003; Burgos et al. 2004; Smith et al. 2007).
Unfortunately, such isolates are often unculturable,
yielding a very limited amount of DNA for study.
Cryptosporidium, an emergent protozoan parasite
causing mainly diarrhoeal illness in humans and ani-
mals, is particularly diﬃcult to propagate. Although
Cryptosporidium oocysts are excreted in high num-
bers in the faeces during acute clinical episodes
(Goodgame et al. 1993), the puriﬁcation methods
used to obtain clean DNA, suitable for downstream
molecular methods, usually result in losses. This
presents diﬃculties for the study of isolates present
in lower numbers, such as those in environmental
samples or during subclinical infection. These issues
have limited biological studies to C. parvum calf
propagated strains, particularly the IOWA reference
strain (Cama et al. 2006).
Several subtyping techniques have been applied to
Cryptosporidium species using diﬀerent markers:
glycoprotein GP60 (Strong et al. 2000; Leav et al.
2002), double-stranded RNA element (Leoni et al.
2003) and mini- and microsatellite repeats (Caccio`
et al. 2000; Mallon et al. 2003). Ideally, each new
isolate should be tested using a panel of markers.
However, this is usually limited by the amount of
DNA available.Whole genome ampliﬁcation (WGA)
can be used to increase the amount of nucleic acid
available from clinical and environmental samples
of waterborne pathogens (reviewed by Bouzid et al.
2008) and application of this technique to Crypto-
sporidium isolates should address the perceived need
for multilocus typing (Smith et al. 2006).
The ﬁrst described WGA methods were de-
generate oligonucleotide-primed PCR (DOP–PCR)
(Telenius et al. 1992; Cheung and Nelson, 1996) and
primerextensionpreampliﬁcation (PEP) (Zhang et al.
1992). However, these PCR-based techniques pro-
duced short products (<3 kb) and were limited by
substantial ampliﬁcation bias and incomplete cover-
age of geneticmarkers (Paunio et al. 1996; Dean et al.
2002; Hawkins et al. 2002; Park et al. 2005). New
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strategies for WGA have been developed including
multiple displacement ampliﬁcation (MDA) and
OmniPlex WGA (Park et al. 2005). MDA is an
isothermal ampliﬁcation using degenerate hexamers
and the bacteriophage phi-29 DNA polymerase,
which possesses high processivity, strand-displace-
ment abilities and a proof-reading activity resulting
in error rates 100 times lower than the Taq poly-
merase (Eckert and Kunkel, 1991; Esteban et al.
1993; Dean et al. 2002; Nelson et al. 2002; Hawkins
et al. 2002). MDA was ﬁrst described by Blanco
et al. (1989) and then used for WGA of diﬀerent
targets such as lymphoma and leukaemia clinical
specimens (Luthra and Medeiros, 2004), complex
mixtures of DNA (Shoaib et al. 2008), whole blood
and tissue-culture cells (Dean et al. 2002), human
blastomeres (Snabes et al. 1994), plasmid constructs
and whole bacterial genomes (Detter et al. 2002).
The OmniPlex WGA technique uses libraries of
200–2000 bp fragments created by random chemical
cleavage of genomic DNA, followed by ligation of
adaptor sequences to both ends and PCR ampliﬁ-
cation (Barker et al. 2004; Bergen et al. 2005). This
fragmentation/ligation/PCR-basedmethod ampliﬁes
the entire genome several 1000-fold, and could be
even re-ampliﬁed to achieve a ﬁnal ampliﬁcation of
over 1 000 000-fold without introducing inaccuracies
(Langmore, 2002). Currently, several commercial
kits for MDA and Omniplex based WGA are avail-
able.
We report here the results of the ﬁrst study to
evaluate the suitability of WGA for the accurate
expansion of genomic DNA from Cryptosporidium
isolates using commercial kits.
MATERIALS AND METHODS
Cryptosporidium DNA
Ten clinical samples were selected from the collec-
tion of the Cryptosporidium reference unit (CRU),
Swansea. They originated from diarrhoea patients
with conﬁrmed cryptosporidiosis from diﬀerent geo-
graphical locations in theUK.DNAwas isolated from
semi-puriﬁed oocyst suspensions prepared from stool
samples by saturated-salt solution centrifugation
and extracted using QIAamp DNA mini kit spin
columns (Qiagen Ltd, Crawley, UK) as previously
described by Elwin et al. (2001). For each sample,
the speciation was performed by PCR-RFLP of the
Cryptosporidium oocyst wall protein (COWP) gene as
previously described by Spano et al. (1997) and by
real-time PCR using simplex Lib 13 primers for C.
parvum and C. hominis as described by Tanriverdi
et al. (2003). For this study, we tested the DNA of 5
C. hominis and 5 C. parvum isolates as these two
species are the cause of the majority of human cases
of cryptosporidiosis. Table 1 detailed the origin and
the epidemiological data of the tested isolates.
All DNA samples were quantiﬁed by spectrometry
usingNanodropND-1000 (ThermoFisher Scientiﬁc,
Leicestershire, UK). In addition, C. parvum IOWA
reference strain DNA extracted from a puriﬁed
oocyst suspension from a commercial source (ATCC/
LGC Promochem, Teddington, UK) was tested as
a positive control and its DNA concentration was
quantiﬁed as 5.8 ng/ml.
WGA kits
Three commercial WGA kits were tested during
this study: illustra GenomiPhi V2 DNA ampliﬁ-
cation Kit (GE Healthcare, Buckinghamshire, UK),
REPLI-g Ultra-fast Mini Kit (Qiagen, Crawley,
UK)andGenomePlex1CompleteWGAKit (Sigma,
Dorset, UK). Illustra GenomiPhi and REPLI-g kits
are MDA-based WGA, while GenomePlex kit is
based on the Omniplex technique. All 3 kits were
used according to the manufacturer’s instructions.
The manufacturer’s recommended starting genomic
DNA concentration was 1 ng for the illustra kit and
10 ng for both the REPLI-g and GenomePlex kits.
Table 1. Origin and epidemiological data of clinical isolates of Cryptosporidium hominis and C. parvum
used for this study
(The concentration of each DNA suspension was evaluated by nanodrop.)
Sample
reference
Age
of case
Gender
of case
Origin
of case
RFLP of the
COWP gene
(speciation)
DNA
concentration
(nanodrop ng/ml)
W15504 43 F Scotland C. hominis 12
W15507 9 F Wales C. hominis 4.3
W15508 31 Not stated England C. hominis 3.5
W15519 68 F England C. hominis 5.5
W15521 14 F Scotland C. hominis 11.5
W15509 12 Not stated England C. parvum 6.7
W15511 19 F Scotland C. parvum 6.2
W15516 21 F England C. parvum 8.9
W15517 12 M England C. parvum 6.4
W15518 2 M England C. parvum 13.2
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As the DNA concentrations of Cryptosporidium iso-
lates ranged from 3.5 to 13.2 ng/ml (with a mean of
7.7 ng/ml), 1 ml of each sample was used for WGA.
WGA techniques are well established in the litera-
ture to give ampliﬁcation levels from 10-fold less
than our lowest template concentration (0.3 ng)
to 20-fold higher than our highest concentration
(300 ng) (Dean et al. 2002), which raises the prospect
for them to be usedwidely for clinical samples. Thus,
in our study all of the samples lie well within the
range we would expect to give good ampliﬁcation by
the kits under test and the range recommended by
the manufacturers.
Quantiﬁcation of genomic DNA after WGA
After WGA, the ampliﬁed products were analysed
by agarose gel electrophoresis. In addition, 3methods
were used to quantify the ampliﬁed genomic DNA:
Nanodrop, Hoechst and PicoGreen. Hoechst 33258
dye exhibits enhanced ﬂuorescence when bound
to dsDNA under high ionic strength conditions
(Goumenou and Machera, 2004). Serial dilutions of
calf thymus DNA stock solution (1 mg/ml) (Sigma,
Dorset, UK) were performed yielding concen-
trations ranging from 100 ng/ml to 2500 ng/ml. Fifty
ml of each preparation was used for measurement. All
DNA samples were diluted in TNE buﬀer (100 mM
Tris, 1 MNaCl, 10 mMNa2EDTA, pH 7
.5). For each
DNA sample, an equal volume of 2x Hoechst Dye
solution (200 ng/ml) (Sigma, Dorset, UK) was
added. Fluorescence was read using a microplate
reader FLUOstar, BMG Labtech (Aylesbury, UK)
after incubation for 5 min at room temperature. The
blank solution was prepared by adding an equal
volume of TNE buﬀer and 2x dye solution. The
average value of the blank measurement was sub-
tracted from the measurements made at each con-
centration and the results plotted. A linear regression
was performed on the standard curve to allow the
determination of the DNA concentrations of the
tested samples. PicoGreen was also used as an ultra-
sensitive ﬂuorescent nucleic acid stain for accurate
quantiﬁcation of double-stranded DNA (dsDNA).
Quanti-iTTM Picogreen1 dsDNA kit (Molecular
Probes, Invitrogen, Paisley, UK) was used according
to the manufacturer’s instructions. We also used
GeneTools software (Syngene, Cambridge, UK) for
densitometry-based DNA quantiﬁcation.
Integrity and ﬁdelity of ampliﬁed genomic DNA
The integrity of the ampliﬁed DNA for the 3 kits
was evaluated by PCR using Cry15/Cry 9 primers
amplifying 550 bp of the COWP gene (Spano et al.
1997). In addition, 2 newly designed primers were
also used, amplifying 270 bp and 247 bp of Cgd6_
5020 and Chro.20156 genes, respectively. COWP
and Cgd6_5020 markers are on Chromosome 6 and
Chro.20156 gene is on Chromosome 2. The primer
sequences were as follows: Cgd6_5020F (AACAG
GAGCTGACGATTGCT), Cgd6_5020R (ACAT
TGTGCCATTCCAAGGT), Chro.20156F (TTC
GCTTGAAGCCGTAAACT) and Chro20156R
(GGCATTGATACCAGGCAAGT). All DNA
templates were diluted 1/25 after WGA, PCR con-
ditions were the same for genomic DNA and for
post-WGA subsequent ampliﬁcations. The PCR
mix for each primer set consisted of 1.5 mM MgCl2,
0.2 mM of each dNTP (Bioline, UK), 0.6 mM of each
primer and 2.5 U of HotStar Taq DNA polymerase
(Qiagen Ltd, Crawley, UK) in a 50 ml ﬁnal volume.
The cycling conditions were as follows: an initial
hot-start at 95 xC for 15 min, followed by 40 cycles of
94 xC for 50 s, 57 xC for 30 s and 72 xC for 50 s and a
ﬁnal extension at 72 xC for 10 min. The PCR re-
actions were performed using Techne TC-512 ther-
mal cycler (SLS, Nottingham, UK). PCR products
were run on a 2% agarose gel stained with ethidium
bromide in TBE buﬀer and visualized under UV.
The ﬁdelity of the ampliﬁcation was assessed by
PCR product sequence analysis before and after
WGA of 2 C. hominis samples (W15507, W15519),
2 C. parvum samples (W15511, W15516) and the
reference strain C. parvum IOWA. PCR products
were puriﬁed using QIAquick1 PCR puriﬁcation
Kit (Qiagen Ltd, Crawley, UK) and were sequenced
using the Big-Dye Terminator cycle sequencing
system and an ABI 3770 DNA sequencer at the
genome lab, John Innes Centre (www.jic.ac.uk).
The sequences were aligned using Vector NTI
AdvanceTM 10 (Invitrogen, Paisley, UK).
Comparative analysis of Cryptosporidium genomic
DNA before and after WGA
The comparative analysis of genomic DNA and
paired WGADNAwas limited to the samples which
were prepared using the most promising WGA
method as explained below. After WGA, the ampli-
ﬁed products were compared to the original genomic
DNA using a species-speciﬁc, semi-quantitative
real-time PCR assay. Brieﬂy, real-time PCR using
simplex Lib 13 primers forC. parvum andC. hominis
(Tanriverdi et al. 2003) was used in triplicate to
amplify 2 ml of genomic DNA and 2 ml of its paired
WGA DNA (both diluted 1 in 25 v/v). We used
Corbett Rotorgene 3000 platform (Corbett Life
Science, Sydney, Australia). Melt curve analysis was
performed to identify Cryptosporidium species and
CT (threshold cycle) valueswere recorded to compare
each paired sample, before and after WGA. This as-
say shows a demonstrable diﬀerence of 3 CT units per
10-fold diﬀerence inDNA target copynumber (CRU
unpublished data). Since the WGA DNA originated
from 1 ml of genomic DNA producing 10 ml of prod-
uct (representing a 10-fold dilution in comparison
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with the genomic DNA), the ﬁnal CT values for the
WGADNA were decreased by 3 CT units.
RESULTS
Success rate and yield of WGA kits
The reliability and robustness of WGA kits to vari-
ation in DNA acquired from clinical samples were
assessed by agarose gel electrophoresis. A successful
ampliﬁcation was considered when genomic DNA
was visible on the gel. One sample W15508 did not
amplify with any of the 3 kits tested.
Illustra GenomiPhi and REPLI-g kit-ampliﬁed
DNA was of high molecular weight (y10 kb) for all
the tested samples. The success rate was 90.91%
(10/11samples) for illustraGenomiPhikitand45.46%
(5/11) for REPLI-g kit (Fig. 1). For GenomePlex
ampliﬁed samples, the generated DNA was of
smaller size ranging between 200 and 1000 bp
(mean size y400 bp) (Fig. 1). The success rate was
72.73% (8/11 samples). For illustra GenomiPhi and
REPLI-g kits, samplesW15521,W15516 and IOWA
showed the strongest bands, suggesting better am-
pliﬁcation. However, when the GenomePlex kit was
used, W15504, W15521, W15516 and W15517
showed a high level of ampliﬁcation, but, surpris-
ingly commercially obtained IOWA DNA did not.
DNA quantiﬁcation after WGA was initially as-
sessed by 4 methods: nanodrop spectraphotometry
alone, Hoechst and PicoGreen ﬂuorimetry and
agarose gel-based ethidium bromide ﬂuorescence
densitometry. Presumably because of the presence of
residual random hexamers in the reaction mix (Ahn
et al. 1996; Singer et al. 1997) the ﬁrst 2 methods
required additional puriﬁcation before DNA quanti-
ﬁcation, PicoGreen quantiﬁcation gave good quan-
titative data for 2 of the 3 kits tested (illustra
GenomiPhi and GenomePlex kits) but only gel-
based densitometry was able to provide DNA
concentrations for all 3 kits without an additional
puriﬁcation step.
The results of WGA for the samples tested are
summarized in Table 2. For each kit, yield was de-
termined by calculating the amount of DNA in the
ﬁnal reaction volume (10 ml for illustra GenomiPhi
and 75 ml forGenomePlex kit). Level of ampliﬁcation
was determined as a ratio of concentrations between
template and WGA DNA for each sample. The
typical yield of illustra GenomiPhi kit was 0.7–7 mg
range. The highest yield was 10 mg achieved from
IOWADNAgiving over 180-fold ampliﬁcation. The
typical yield of GenomePlex kit gave a 4.5–46 mg
range and the level of ampliﬁcation was 10 to 70-fold.
For the REPLI-g kit the yield was of a 0.6–2 mg range
illustra 
GenomiPhi kit 
REPLI-g kit 
GenomePlex kit 
MW  1   2   3  4 5 6   7   8    9  10  11 
MW 1   2 3 4  5   6 7  8 9  10  11
MW   1 2   3   4   5 6   7   8    9  10 11 
1500 bp 
  500 bp 
1500 bp 
  500 bp 
1500 bp 
  500 bp 
Fig. 1. Agarose gel electrophoresis of 8 ml of ampliﬁed genomic DNA. MW: molecular weight marker, 1: W15504,
2: W15507, 3: W15508, 4: W15519, 5: W15521 (1–5: Cryptosporidium hominis samples), 6: W15509, 7: W15511,
8: W15516, 9: W15517, 10: W15518 (6–10: C. parvum), 11: C. parvum IOWA.
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(ﬁnal volume 20 ml), corresponding to 50 to 160-fold
ampliﬁcation.
Integrity of ampliﬁed DNA
The integrity of the ampliﬁed genomic DNA was
assessed by PCR using 3 primer sets. For Cry 15/9
primers, amplifying a 550 bp of the COWP gene, all
11 samples were positive before WGA (data not
shown). After WGA, 10/11 illustra GenomiPhi
ampliﬁed samples (91%), 6/11 REPLI-g ampliﬁed
samples (54.6%) and 9/11 GenomePlex ampliﬁed
samples (81.9%) were PCR positive (Fig. 2). For
Cgd6_5020 primers, amplifying 270 bp, all 11 sam-
ples were also positive before WGA. After WGA,
10/11 illustra GenomiPhi ampliﬁed samples (91%),
8/11 REPLI-g ampliﬁed samples (72.8%) and 11/11
GenomePlex ampliﬁed samples (100%) were PCR
positive (data not shown). For Chro.20156 primers,
amplifying 247 bp, 10/11 samples were positive be-
fore WGA, only W15519 sample was negative (data
not shown). After WGA, 9/11 illustra GenomiPhi
ampliﬁed samples (81.9%), 7/11 REPLI-g ampliﬁed
samples (63.7%) and 11/11 GenomePlex ampliﬁed
samples (100%)were PCRpositive. The overall post-
WGA PCR success rates from the 3 kits were
87.88%, 63.64% and 93.94% for illustra GenomiPhi,
REPLI-g andGenomePlex kits, respectively (Table 2).
Fidelity of WGA kits
The ﬁdelity of ampliﬁcation was assessed by PCR
product sequence analysis, generated with and
without a WGA intermediate step. For Cry 15/9
primers, PCR product sequences were identical
using all 3 kits for W15507, W15511 and IOWA
isolates (supplemental data). For W15516 isolate,
WGA using REPLI-g kit produced 3 nucleotide
errors and the use of GenomePlex kit produced
1 error, corresponding to 99.34% and 99.78% se-
quence concordance, respectively. For Cgd6_5020
and Chro.20156 primers, PCR product sequences
were identical before and after WGA for all the
samples. The overall ﬁdelity of the 3 kits was 100%,
99.62% and 99.87% for illustra GenomiPhi, REPLI-g
and GenomePlex kits, respectively (Table 2).
Interestingly, one of the samples tested (W15519)
failed to amplify using Chro.20156 primers without
WGA or after WGA using illustra GenomiPhi and
REPLI-g kits, but did amplify when GenomePlex
ampliﬁed DNA was used. The identity of the PCR
product was conﬁrmed by sequencing.
Comparative analysis of Cryptosporidium genomic
DNA before and after WGA
Melt curve analysis of genomic DNA and WGA
DNA ampliﬁed using the Illustra GenomiPhi
conﬁrmed that the same species of CryptosporidiumT
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was present before and after WGA in each of the
samples tested (data not shown). The unadjusted CT
values show that 8/11 of the samples had a lower CT
after WGA than before, indicating that in these
samples the WGA did amplify Cryptosporidium
DNA. After adjustment to allow for the 10-fold
dilution applied through theWGA process, all of the
samples had a lower CT value after WGA conﬁrming
that Cryptosporidium DNA was present in higher
copy numbers in the samples post-WGA than before
(Table 3). The highest diﬀerence of CT before and
after WGA was 10.13 for sample W15516, which
corresponds to over 30-fold increase in DNA target
copy number. This is in accordance with the overall
level of ampliﬁcation. For the other samples, the
diﬀerence in CT values before and afterWGA ranged
between 2.63 (for sample W15504) and 8.11 (for
sample W15511), corresponding to an 8 to 27-fold
increase in copy numbers. For sample W15508, the
diﬀerence in CT value was 0
.73 supporting a poor
ampliﬁcation.
DISCUSSION
In this study, we successfully usedWGA commercial
kits for ampliﬁcation of Cryptosporidium genomic
DNA from clinical isolates. The Illustra GenomiPhi
and GenomePlex kits successfully ampliﬁed the
majority of the tested isolates (90.91% and 72.73%,
respectively). The REPLI-g Kit, however, ampliﬁed
less than half of the samples. One sampleW15508 did
not amplify with any of the 3 kits tested, while the
reason for this cannot be known and the template
concentration was well within the recommended
range for the kits under test, it did correlate with the
sample having the lowest concentration of template
DNA tested and thus may reﬂect some degree of
degradation of the DNA in that sample or relative
enrichment of inhibitors carried through the DNA
puriﬁcation process.
For MDA-based kits (illustra GenomiPhi and
REPLI-g), the ampliﬁed DNA was of high molecu-
lar weight. It was noticeable that most of the DNA
remains in the well when run out on an agarose gel,
this is likely due to the formation of very high
molecular weight DNA forms, independent of the
genome size, as previously reported by Detter et al.
(2002). OmniPlex-ampliﬁed DNA was of smaller
size, which is due to the method used, involving
fragmentation of the genomic DNA followed by
linker ligation to enable ampliﬁcation (Thorstenson
et al. 1998; Fiegler et al. 2007).
illustra
GenomiPhi kit 
REPLI-g kit 
GenomePlex kit 
 MW 1  2   3   4  5 6  7 8  9  10   11 NTC 
 MW 1  2   3  4 5    6   7   8     9   10 11 NTC 
MW 1  2 3  4 5    6   7 8    9   10 11 NTC 
600 bp 
600 bp 
500 bp 
Fig. 2. PCR products of WGA ampliﬁed Cryptosporidium DNA isolates using Cry15/9 primers. MW: molecular
weight marker, 1: W15504, 2: W15507, 3: W15508, 4: W15519, 5: W15521, 6: W15509, 7: W15511, 8: W15516, 9:
W15517, 10: W15518, 11: C. parvum IOWA, NTC: non-template control.
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PicoGreen DNA quantiﬁcation of the ampliﬁed
DNA proved eﬀective for Illustra GenomiPhi and
GenomePlex kits. The yield range was 0.7–10 mg and
4.5–46 mg, respectively, which is in accordance with
the manufacturer’s claims. The apparent higher
yield of GenomePlex kit corresponds with a higher
reaction volume (10 ml versus 75 ml). In our hands,
the PicoGreen quantiﬁcation of REPLI-g kit
ampliﬁed samples was not eﬀective without prior
puriﬁcation of the ampliﬁed DNA.
The integrity of the ampliﬁed DNA was assessed
by the ability to generate PCR product for 3 genetic
loci and 87.88% (29/33), 63.64% (21/33) and 93.94%
(31/33) of Cryptosporidium samples, ampliﬁed by
illustra GenomiPhi, REPLI-g andGenomePlex kits,
respectively, were PCR positive. For 1 sample,
the W15519 isolate, no PCR ampliﬁcation using
Chro.20156 primers was observed before WGA or
after WGA using illustra GenomiPhi and REPLI-g
kits. However, GenomePlex ampliﬁed DNA of the
same sample was PCR positive and the identity of the
PCR product was conﬁrmed by sequencing. These
results suggest that the use of WGA-ampliﬁed DNA
as PCR template can sometimes actually increase
PCR sensitivity from clinical samples. Similar ﬁnd-
ings were reported for the detection of Trypanosoma
species from blood samples (Pinchbeck et al. 2008).
Further work to more thoroughly test the integrity
of the ampliﬁed DNA and assessing ampliﬁcation
biases should focus on ampliﬁcation of longer se-
quences and broader genomic coverage utilizing se-
quences from each of the 8 nuclear chromosomes,
from the telemeres, centromeres, ribosomal DNA,
mitochondrial DNA, and repetitive regions.
The ﬁdelity of the ampliﬁcation was assessed by
PCR products sequence analysis before and after
WGA. In our hands, for this sample set, the overall
error rate observed was 0% for illustra GenomiPhi
kit, 0.38% for REPLI-g kit and 0.13% for Genome-
Plex kit. Interestingly, all the errors arose from the
same clinical sample using the same set of primers.
This could be explained by a variety of factors such
as the presence of impurities aﬀecting the enzyme
proof-reading activity, the secondary structure of the
DNA, or by a low concentration of the starting
material, which can decrease the ampliﬁcation
ﬁdelity as reported by Bergen et al. (2005). It is also
important to bear in mind that although the se-
quences analysed were short ones, both the second-
ary ampliﬁcation step and the sequencing step have
the potential to introduce errors which would not be
discriminated from errors arising during the WGA.
Sequence analysis of WGA ampliﬁed PCR
products using Cry 15/9 primers showed the pres-
ervation of 6 species-speciﬁc Single Nucleotide
Polymorphisms (SNP)s, one of which at position 66
is of particular interest as it corresponds to an RsaI
restriction site used for Cryptosporidium genotyping
as previously described (Spano et al. 1997). In
addition, sequence analysis showed the preservation
of 1 species-speciﬁc SNP for Cgd6_5020 gene and
5 species-speciﬁc SNPs for Chro.20156.
Comparative analysis of Cryptosporidium genomic
DNA and paired WGA DNA using real-time PCR
Table 3. Real-time analysis of Cryptosporidium DNA before and after
WGA and estimation of the increase in copy numbers after WGA using
the illustra GenomiPhi kit
Sample
Genomic DNA/
WGA DNA
Mean CT
(adjusted)
CT value
diﬀerence
Increase in
copy numbers
15504 Genomic DNA 31.63 2.63 8.8
WGA DNA 29.00
15507 Genomic DNA 22.62 4.53 15
WGA DNA 18.09
15508 Genomic DNA 29.06 0.73 2.5
WGA DNA 28.33
15519 Genomic DNA 32.56 2.54 8.5
WGA DNA 30.02
15521 Genomic DNA 23.72 4.41 14.8
WGA DNA 19.31
15509 Genomic DNA 28.82 4.09 13.7
WGA DNA 24.73
15511 Genomic DNA 23.57 8.11 27
WGA DNA 15.46
15516 Genomic DNA 29.57 10.13 33.8
WGA DNA 19.44
15517 Genomic DNA 28.87 4.08 13.6
WGA DNA 24.79
15518 Genomic DNA 25.99 7.81 26
WGA DNA 18.18
IOWA Genomic DNA 19.15 7.96 26.6
WGA DNA 11.46
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assay conﬁrmed that Cryptosporidium DNA was
speciﬁcally ampliﬁed using illustra GenomiPhi kit,
resulting in higher copy numbers post-WGA than
before for all the samples tested.
These results were obtained from semi-puriﬁed
oocyst suspensions, themselves requiring reasonable
numbers of oocysts in the original sample. They
carry signiﬁcant contamination of bacterial, fungal
and even animal DNAs also ampliﬁed by the process.
Real-time PCR for faecal marker DNAs such as
genes from E. coli might be useful to determine
whether there is any predisposition to amplifying
contaminating DNAs rather than the cryptospori-
dium DNA in the samples. Additional investigation
of the eﬀect of other oocyst puriﬁcation methods
(immunomagnetic separation) on the performance of
WGA should also be performed. Importantly, since
many investigators use DNA extracted from raw
stool without prior oocyst puriﬁcation, independent
validation of the suitability of this material for WGA
and downstream analysis should also be undertaken.
For our collection of Cryptosporidium clinical
isolates, illustra GenomiPhi WGA kit had the best
performance, with 90.91% success rate, generating a
high concentration of high molecular weight DNA
with 100% ﬁdelity. The additional cost of WGA
is not prohibitive for clinical usage – using illustra
GenomiPhi kit based on the 2009 recommended re-
tail price in the UK the cost is roughly £3.60 per
sample added to the PCR cost for routine detection
of Cryptosporidium DNA. These are preliminary
results, highlighting the usefulness of MDA based
WGA for the accurate ampliﬁcation of Cryptospori-
dium genomic DNA for the purposes of immortal-
ization of clinical isolates and enabling extensive
genetic testing.
This study investigated the suitability of Crypto-
sporidiumDNA afterWGA for genotyping purposes.
We tested COWP marker as it is routinely used
for Cryptosporidium speciation by RFLP, together
with 2 novel markers. Our results showed eﬃcient
and speciﬁc ampliﬁcation of Cryptosporidium DNA.
Further validation of these WGA techniques for
routine subtyping ofCryptosporidium (GP60, double-
stranded RNA and mini and micro-satellite repeats)
would be necessary and desirable before adopting
WGA for routine characterization of clinical and
environmental isolates of Cryptosporidium species.
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